Nivolumab, Ipilimumab and Chemoradiation in Treating Patients with Resectable Gastric Cancer
Phase 2
Active, not recruiting
- Conditions
- Clinical Stage 0 Gastric Cancer AJCC V8Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IIB Gastric Cancer AJCC V8Clinical Stage I Gastric Cancer AJCC V8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8Clinical Stage IVA Gastric Cancer AJCC V8Gastric AdenocarcinomaClinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8
- Interventions
- Drug: FluorouracilRadiation: Intensity-Modulated Radiation TherapyBiological: IpilimumabBiological: NivolumabDrug: OxaliplatinProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03776487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders
Not Applicable
Completed
- Conditions
- Bile Duct DisorderEndocrine Pancreas Disorder
- Interventions
- Procedure: Endoscopic Retrograde CholangiopancreatographyOther: InterviewDevice: Laryngeal Mask Airway
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT03775681
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
Phase 1
Completed
- Conditions
- Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03774472
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients with Prostate Cancer
Phase 2
Recruiting
- Conditions
- Prostate Carcinoma
- Interventions
- Behavioral: Exercise InterventionOther: Quality-of-Life AssessmentOther: PlaceboDrug: MethylphenidateOther: Questionnaire AdministrationOther: Stretching
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT03772834
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
Phase 2
Active, not recruiting
- Conditions
- Recurrent Central Nervous System LymphomaRefractory Central Nervous System LymphomaCentral Nervous System B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03770416
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Active, not recruiting
- Conditions
- Refractory Plasma Cell MyelomaRecurrent Plasma Cell Myeloma
- Interventions
- Drug: BortezomibBiological: DaratumumabDrug: DexamethasoneDrug: IxazomibOther: Quality-of-Life Assessment
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03763162
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Malignant Solid NeoplasmOvarian CarcinomaRefractory Malignant Solid NeoplasmRefractory Ovarian Carcinoma
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT03756818
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Flexible Intubation Scope With or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients With Head and Neck Cancer Before Surgery
Not Applicable
Recruiting
- Conditions
- Head and Neck Neoplasm
- Interventions
- Procedure: Tracheal IntubationDevice: Laryngoscopy
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT03757091
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Phase 1
Recruiting
- Conditions
- Anaplastic EpendymomaEpendymoma
- Interventions
- Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton TherapyOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT03750513
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Refractory Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- Drug: Expansion Phase TK216Drug: Expansion Phase Decitabine
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03752138
© Copyright 2025. All Rights Reserved by MedPath